1.810USD-2.95%Mkt Cap: 338.14M USDP/E: —Last update: 2026-06-01
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. Th…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap338.14M USD
Enterprise Value225.64M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-236.93M USD
Revenue/Share—
Last Price1.810 USD
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees96
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.08
PEG—
EV/EBITDA-0.96
EV/Revenue—
P/S—
P/B3.10
EPS (TTM)-1.33
EPS (Forward)-0.89
52W Range
0.690038% of range3.650
52W High3.650 USD
52W Low0.6900 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-228.10%
ROA-124.02%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-206.44M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-34.22%
Net Debt-127.52M USD
Net Debt/EBITDA0.54
Balance Sheet
Debt/Equity0.53
Current Ratio5.87
Quick Ratio5.63
Book Value/Sh0.5960 USD
Cash/Share1.003 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.8 (Buy)
Target (Mean)8.908 USD
Target Range3.000 USD – 18.00 USD
# Analysts8
Ownership
Shares Out.185.28M
Float104.83M
Insiders23.93%
Institutions55.90%
Short Interest
Short Ratio3.8d
Short % Float4.27%
Short % Out.2.45%
Shares Short4.47M
Short (prev mo.)4.96M
Technical
SMA 502.125 (-14.8%)
SMA 2002.195 (-17.5%)
Beta3.05
S&P 52W Chg27.94%
Avg Vol (30d)1.36M
Avg Vol (10d)1.14M
Technical Indicators
RSI (14)44.3
MACD-0.1024
MACD Signal-0.1184
MACD Hist.+0.0160
BB Upper2.381 USD
BB Middle1.940 USD
BB Lower1.499 USD
BB Width45.44%
ATR (14)0.1623 USD
Vol Ratio (20d)0.49x